What is Minimal Residual Disease (MRD) in myeloma?

Sustained MRD negativity for three years can guide discontinuation of LEN maintenance in myelomaПодробнее

The association between MRD and PFS in myelomaПодробнее

Challenges that remain regarding the use of cfDNA for MRD detection in myeloma: cost and sensitivityПодробнее

Using MRD after autoSCT as a benchmark for consolidation strategies in myelomaПодробнее

Final results of the DART4MM study of daratumumab for MRD eradication in myelomaПодробнее

The impact of MRD in apheresis product in patients with myeloma undergoing autoSCTПодробнее

Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trialsПодробнее

Whole genome sequencing of cfDNA as a non-invasive method for MRD detection in multiple myelomaПодробнее

OncoAlert Session Round Up at #ASH24 in Multiple Myeloma: Advancing Minimal Residual Disease (MRD)Подробнее

Mass spectrometry-based technologies for MRD detection in myeloma: insights into the BLOOM studyПодробнее

Predictors of unsustained MRD negativity in transplant-eligible patients with multiple myelomaПодробнее

The Benefit of Detecting Minimal Residual Disease in MMПодробнее

How to monitor during induction therapy and role of MRD in Multiple MyelomaПодробнее

Can peripheral blood MRD monitoring supplement bone marrow monitoring?Подробнее

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024Подробнее

The potential of MRD-adapted treatment in multiple myelomaПодробнее

The real world utilization of MRD in myeloma across EuropeПодробнее

The value of MRD as an early endpoint in multiple myeloma clinical trialsПодробнее

Is MRD Negativity the Goal of Myeloma Treatment?Подробнее

Will MRD change how we think about success in MM treatment?Подробнее